



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,950	12/24/2003	Jean-Louis Henri Dassoux	10173-112-999 (CAM #37185	9582
20583	7590	08/03/2005		EXAMINER
JONES DAY				AULAKH, CHARANJIT
222 EAST 41ST ST				
NEW YORK, NY 10017			ART UNIT	PAPER NUMBER
			1625	

DATE MAILED: 08/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/743,950	DASSEUX ET AL.
	Examiner	Art Unit
	Charanjit S. Aulakh	1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on ____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-57 is/are pending in the application.
 - 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) Claim(s) ____ is/are allowed.
- 6) Claim(s) ____ is/are rejected.
- 7) Claim(s) ____ is/are objected to.
- 8) Claim(s) 1-57 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. ____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____.

- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: ____.

DETAILED ACTION

1. Claims 1-57 are pending in the application.

Election/Restrictions

2. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-17, 20 and 34-57, drawn to compounds of formula I where G represents $(CH_2)_x$, Z is CH₂ and both W₁ and W₂ do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 558, subclass 20.

II. Claims 1-20 and 34-57, drawn to compounds of formula I where G represents $(CH_2)_x$, Z is CH₂ and both W₁ and W₂ do represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 549, subclass 356.

III. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $(CH_2)_x$, Z is CH=CH and both W₁ and W₂ do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 560, subclass 8.

IV. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $(CH_2)_x$, Z is CH=CH and both W₁ and W₂ do represent a heteroaryl or

heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 548, subclass 317.1.

V. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $(CH_2)_x$, Z is phenyl and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 562, subclass 125.

VI. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $(CH_2)_x$, Z is phenyl and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 546, subclass 114.

VII. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $CH_2CH=CHCH_2$ or $CH=CH$, Z is CH_2 and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 558, subclass 70.

VIII. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $CH_2CH=CHCH_2$ or $CH=CH$, Z is CH_2 and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions

containing these compounds and a method of using these compounds, classified in class 549, subclass 273.

IX. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $\text{CH}_2\text{CH}=\text{CHCH}_2$ or $\text{CH}=\text{CH}$, Z is $\text{CH}=\text{CH}$ and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 560, subclass 129.

X. Claims 1-14 and 34-57, drawn to compounds of formula I where G represents $\text{CH}_2\text{CH}=\text{CHCH}_2$ or $\text{CH}=\text{CH}$, Z is $\text{CH}=\text{CH}$ and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 548, subclass 250.

XI. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents $\text{CH}_2\text{CH}=\text{CHCH}_2$ or $\text{CH}=\text{CH}$, Z is phenyl and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 562, subclass 8.

XII. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents $\text{CH}_2\text{CH}=\text{CHCH}_2$ or $\text{CH}=\text{CH}$, Z is phenyl and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions

containing these compounds and a method of using these compounds, classified in class 546, subclass 152.

XIII. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents CH2-phenyl-CH2 or phenyl, Z is CH2 and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 558, subclass 303.

XIV. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents CH2-phenyl-CH2 or phenyl, Z is CH2 and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 548, subclass 100.

XV. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents CH2-phenyl-CH2 or phenyl, Z is CH=CH and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 568, subclass 303.

XVI. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents CH2-phenyl-CH2 or phenyl, Z is CH=CH and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions

containing these compounds and a method of using these compounds, classified in class 548, subclass 146.

XVII. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents CH₂-phenyl-CH₂ or phenyl, Z is phenyl and both W₁ and W₂ do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 568, subclass 420.

XVIII. Claims 1-8 and 34-57, drawn to compounds of formula I where G represents CH₂-phenyl-CH₂ or phenyl, Z is phenyl and both W₁ and W₂ do represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 548, subclass 240.

XIX. Claims 21-25 and 34-57, drawn to compounds of formula IIa, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 568, subclass 579.

XX. Claims 26-57, drawn to compounds of formula III or IIIa where G represents (CH₂)_x and both W₁ and W₂ do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 568, subclass 700.

XXI. Claims 26-57, drawn to compounds of formula III or IIIa where G represents (CH₂)_x and both W₁ and W₂ do represent a heteroaryl or heterocyclic

group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 549, subclass 328.

XXII. Claims 26-57, drawn to compounds of formula III or IIIa where G represents $\text{CH}_2\text{CH}=\text{CHCH}_2$ or $\text{CH}=\text{CH}$ and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 568, subclass 840.

XXIII. Claims 26-57, drawn to compounds of formula III or IIIa where G represents $\text{CH}_2\text{CH}=\text{CHCH}_2$ or $\text{CH}=\text{CH}$ and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 548, subclass 262.2.

XXIV. Claims 26-57, drawn to compounds of formula III or IIIa where G represents $\text{CH}_2\text{-phenyl-CH}_2$ or phenyl and both W1 and W2 do not represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 560, subclass 75.

XXV. Claims 26-57, drawn to compounds of formula III or IIIa where G represents $\text{CH}_2\text{-phenyl-CH}_2$ or phenyl and both W1 and W2 do represent a heteroaryl or heterocyclic group, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 546, subclass 290.

3. The inventions I through XXV as defined above are patentably distinct, each from the other since they are structurally so divergent that a reference showing compounds of invention I would not render compounds of inventions II through XXVI *prima facia* obvious. Search required for e.g ; compounds of invention I in class 558, subclass 20 is not the same search required for e.g ; compounds of invention II in class 549, subclass 356 and therefore, constitutes a burdensome search.

4. A telephone call was made to the applicant's attorney, Mr. Anthony M. Insogna on July 29, 2005 to request an oral election to the above restriction requirement, but did not result in an election being made.


Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is (571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571)272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


Charanjit S. Aulakh
Primary Examiner
Art Unit 1625